Below are recently opened clinical trials that are currently available at Fox Chase Cancer Center. To refer a patient to any of these studies, please call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
Featured Clinical Trials
News
These hyper-proliferative myeloid malignancies are associated with the mutations in JAK2, CALR, and MPL genes. Current treatment options for these diseases include cyto-reductive therapy with hydroxyurea and the JAK2 inhibitors. Although ...
News
The purpose of this research study is to investigate alternative dosing schedules for the drug cabozantinib. Cabozantinib is a drug with FDA approval for metastatic renal cell carcinoma, but is not approved for the treatment of neuroendocrine ...
News
Enfortumab Vedotin Schedule De-escalation - Clinical Trial
The purpose of this research study is to investigate an alternative dosing schedule for the drug enfortumab vedotin (EV). Enfortumab vedotin is a drug with FDA approval for metastatic urothelial cancer.
News
To evaluate safety and tolerability of treatment with ACTengine® IMA203/IMA203CD8 products as monotherapy or in combination with nivolumab
News
This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or ...
News
This is a prospective, phase II, single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
News
Dose Attenuated Chemotherapy in Compromised Patients with Lung Cancer - Clinical Trial
The purpose of this research study is to determine whether specific, planned adjustments to the doses of the drugs before you receive the first dose will make receiving treatment easier (that is to say, fewer side effects) while keeping ...
News
Study of LP-184 in Patients With Advanced Solid Tumors - Clinical Trial
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available.
Document
DEPARTMENT OF HEMATOLOGY/ONCOLOGY THORACIC CANCERS CLINICAL TRIALS
For general questions about clinical trials, call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
